Frederick G. Hayden

Frederick G. Hayden

Auto-generated profile, based on publicly available information

Frederick G. Hayden

School of Medicine, University of Virginia , Charlottesville, Virginia

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 1999 in JAMA
Verified
Journal Article
Open access
PDF file
FHFrederick G. Hayden
Frederick G. Hayden
JTJohn J. Treanor
John J. Treanor
RFR. Scott Fritz
R. Scott Fritz
MLMonica Lobo
Monica Lobo
RBRobert F. Betts
Robert F. Betts
SSStephen E. Straus
Stephen E. Straus
Research from JAMA — Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza — Randomized Controlled Trials for Prevention and Treatment — ContextInfluenza virus neuraminidase is thought to be essential for virus replication in humans; however, to date, available neuraminidase inhibitors are limited to zanamivir, which is topically administered.ObjectiveTo determine the safety, tolerability, and antiviral activity of oral neuraminidase inhibitor oseltamivir (GS4104/Ro64-0796) for prevention and the early treatment of influenza in experimentally infected humans.DesignTwo randomized, double-blind, placebo-controlled trials conducted between June and July 1997.SettingIndividual hotel rooms; 2 large US university medical schools.ParticipantsA total of 117 healthy adult volunteers (aged 18-40 years; median age, 21 years) who were susceptible (hemagglutination-inhibition antibody titer ≤1:8).InterventionsAll subjects were inoculated intranasally with influenza A/Texas/36/91(H1N1) virus. For the prophylaxis study, oral oseltamivir (100 mg once daily [n=12], 100 mg twice daily [n=12], or matching placebo [n=13], starting 26 hours before virus inoculation) was administered. For the treatment study, the same drug was given (20 mg, 100 mg, or 200 mg twice daily, 200 mg once daily, or matching placebo [n=16], in each group starting 28 hours after inoculation). All regimens were continued for 5 days.Main Outcome MeasuresComparing placebo groups with pooled treatment groups, for prophylaxis, outcomes included frequency of infection and viral shedding; for treatment, viral shedding in titers.ResultsIn the prophylaxis study, 8 (67%) of 12 placebo and 8 (38%) of 21 oseltamivir recipients became infected (P=.16; efficacy, 61%); 6 (50%) placebo compared with 0 oseltamivir recipients shed virus (P<.001; efficacy, 100%), and 33% of placebo but no oseltamivir recipient had infection-related respiratory illness (P<.01). Among infected subjects in the treatment study (n=69), the viral titer area under the curve of the combined oseltamivir groups (n=56) was lower (median [interquartile range {IQR}], 80 [23-151] vs 273 [79-306] log10 tissue culture-infective doses50 per milliliter×hour; P=.02) than the placebo group (n=13), and the median (IQR) duration of viral shedding with therapy was reduced from 107 (83-131) to 58 (35-59) hours (P=.003). Oseltamivir treatment also reduced symptom scores (median [IQR] score-hours, 225 [97-349] vs 400 [189-645]; P=.05), and nasal proinflammatory cytokine levels. Transient mild to moderate nausea after dosing was observed in 15 (17%) of 88 oseltamivir and 2 (7%) of 29 placebo recipients (95% confidence interval for difference, −11% to 68%), which was largely prevented by ingestion with food.ConclusionsIn these trials, prophylaxis and early treatment with oral oseltamivir were both associated with significant antiviral and clinical effects in experimental human influenza.

28 July 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
LKLaurent Kaiser
Laurent Kaiser
CWCynthia Wat
Cynthia Wat
TMTracy Mills
Tracy Mills
PMPaul Mahoney
Paul Mahoney
PWPenelope Ward
Penelope Ward
FHFrederick Hayden
Frederick Hayden
Research from JAMA Internal Medicine — Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations

31 May 2001 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
LKLaurent Kaiser
Laurent Kaiser
RFR. Scott Fritz
R. Scott Fritz
SSStephen E. Straus
Stephen E. Straus
LGLarisa Gubareva
Larisa Gubareva
FHFrederick G. Hayden
Frederick G. Hayden

1 February 2004 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
FHFrederick G. Hayden
Frederick G. Hayden
RBRobert Belshe
Robert Belshe
CVCatalina Villanueva
Catalina Villanueva
RLRiin Lanno
Riin Lanno
CHClaire Hughes
Claire Hughes
JCJackie Carr
Jackie Carr
We determined the efficacy of postexposure prophylaxis (PEP) and treatment of ill index cases with oseltamivir, in an attempt to prevent influenza tr

15 June 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FHFrederick G. Hayden
Frederick G. Hayden
DHDarrell T. Herrington
Darrell T. Herrington
TCTeresa L. Coats
Teresa L. Coats
KKKenneth Kim
Kenneth Kim
ECEllen C. Cooper
Ellen C. Cooper
PGPleconaril Respiratory Infection Study Group
Pleconaril Respiratory Infection Study Group
The novel capsid-binding antiviral pleconaril inhibits in vitro replication of most rhinoviruses and enteroviruses. Oral pleconaril treatment was studied in 2 parallel randomized, double-blind, placebo-controlled trials. Among 1363 picornavirus-infected participants (65%) in the studies combined, the median time to alleviation of illness was 1 day shorter for pleconaril recipients than for placebo recipients (P > .001). Cold symptom scores and frequency of picornavirus cultured from nasal mucus specimens were lower among pleconaril recipients by day 2 of treatment. No treatment effects were seen in those without picornavirus infection. Pleconaril was associated with a higher incidence of nausea (6% vs. 4%) and diarrhea (9% vs. 7%) and with small increases in mean serum cholesterol levels and platelet counts, compared with baseline measurements. A subsequent 6-week prophylaxis study found that pleconaril induces cytochrome P-450 3A enzymes, which metabolize a variety of drugs, including ethinyl estradiol. Early pleconaril treatment was well tolerated and significantly reduced the duration and severity of colds due to picornaviruses in adults.

1 January 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
FHFrederick Hayden
Frederick Hayden
Antiviral agents for the treatment of influenza are urgently needed to circumvent the limitations of current drugs in several critical areas: high fr